SUMMARY. Sarcolemmal transport of L-carnitine was determined in three groups of intact working swine hearts under varying conditions of oxygen delivery and fatty acid (FA) availability. Hearts were regionally perfused with controlled flows to the right, left circumflex (LCF), and left anterior descending (LAD) coronary circulations. All hearts were treated with 50 /iCi [ 14 C]-L-carnitine. Ischemia was induced in the LAD bed by restricting flow by 59% over 30 minutes. Metabolic data were collected both from the LCF (nonischemic) and LAD (ischemic) perfusion beds and compared from three groups of animals: eight untreated control animals (group 1); eight animals perfused similarly to group 1 hearts but additionally treated with excess FA (>1 fimol/ml, group 2); and 10 animals augmented with excess FA as in group 2 but in which oxygen delivery to the LCF and LAD circulations was increased by 56 and 64%, respectively, over levels in group 2. As compared with control data, excess FA further depressed mechanical function in group 2 hearts but not in those receiving high oxygen delivery. Oxygen consumption was higher in FA-treated groups and was regionally decreased in the LAD bed by 49% (range 45-55%) during flow restriction. Significantly greater stores (P < 0.01) of high energy phosphates remained in the LAD bed of hearts with increased oxygen delivery. Ischemia and excess FA treatments separately and together increased tissue stores of long-chain acyl-CoA and carnitine. Labeled L-carnitine was taken up by and distributed into acid soluble and long-chain acyl esters in all groups; the long-chain fraction contained less absolute counts but higher specific activity. Transport rates of L-carnitine decreased modestly with ischemia in all groups. High FA per se effected only slightly greater suppression of uptake. Conversely, hyperperfusion in conjunction with FA treatments (group 3) increased transport significantly (P < 0.01) in both LCf (+70A%) and LAD (+104A%) beds. Thus, carnitine transport at physiological concentrations is in part dependent on rates of coronary flow, even at nonischemic levels. (Ore Res 50: 767-774, 1982) HEARTS exposed to excess fatty acids during coronary ischemia have been reported to have shortened survival and furthered impairments in mechanical, electrical, and metabolic functions (Katz and Messineo, 1981; Liedtke, 1981) . One hypothesis to explain these consequences is a local breakdown of cell membranes and inhibition of critical enzymes effected by the further accumulations of acylated fatty acid derivatives, particularly acyl-CoA. Carnitine, an essential cofactor in fatty acid metabolism which is required for the passage of fatty acids into mitochondria, possesses therapeutic advantages in the ischemic heart (Shug et al., 1975; DiPalma et al., 1975; Vicks et al., 1976; Thomsen et al., 1977; Folts et al., 1978) . We have shown similar effects in excess fat-treated ischemic hearts Liedtke et al., 1981) . Under these conditions, carnitine was noted to improve mechanical function, decrease fatty acid incorporation into the cell, and reduce the buildup of long-chain acyl-CoA.
HEARTS exposed to excess fatty acids during coronary ischemia have been reported to have shortened survival and furthered impairments in mechanical, electrical, and metabolic functions (Katz and Messineo, 1981; Liedtke, 1981) . One hypothesis to explain these consequences is a local breakdown of cell membranes and inhibition of critical enzymes effected by the further accumulations of acylated fatty acid derivatives, particularly acyl-CoA. Carnitine, an essential cofactor in fatty acid metabolism which is required for the passage of fatty acids into mitochondria, possesses therapeutic advantages in the ischemic heart (Shug et al., 1975; DiPalma et al., 1975; Vicks et al., 1976; Thomsen et al., 1977; Folts et al., 1978) . We have shown similar effects in excess fat-treated ischemic hearts Liedtke et al., 1981) . Under these conditions, carnitine was noted to improve mechanical function, decrease fatty acid incorporation into the cell, and reduce the buildup of long-chain acyl-CoA.
Such observations have spurred interest in further detailing carnitine metabolism in heart muscle. In cultured human and isolated rat myocytes Bahl et al., 1980) , carnitine was documented to enter cells against a concentration gradient of at least 60-fold. This entry followed MichaelisMenten kinetics. Incorporation was both temperature and energy dependent, structurally specific for the Lisomer of carnitine, and effectively inhibited by several carnitine precursors as well as 2,4-dinitrophenol and sodium fluoride. The K m of the transport process for carnitine, i.e., the concentration of carnitine at half-maximal uptake, varied from 4.8 fiM in human myocytes to 60 /IM in rat myocytes. Uptake occurred by high and low affinity processes over a range of carnitine concentrations. In the isolated perfused rat heart, Vary and Neely (1981) also demonstrated that carnitine uptake across the sarcolemma occurred by both diffusion and carrier-mediated processes. At physiological concentrations of extracellular carnitine about 80% of the uptake was carrier-mediated. Similar studies have not as yet been conducted in the in vivo, intact, blood-perfused heart, and such was the purpose of these investigations. In particular, the effects of ischemia, hyperperfusion, and excess FA on carnitine uptake were determined. Transport characteristics of the L-isomer only were studied. A model of regional ischemia in intact working swine hearts was used.
Methods

Surgical Preparation
Twenty-six swine, weighing 34-71 kg (average 57.1 ± 2.4 kg), were studied following anesthesia with pentobarbital (35 mg/kg) and the establishment of controlled positive pressure ventilation with 100% oxygen. Specifics of the regionally perfused model, the instrumentation, types, and methods of measurements, and general format of data acquisition have been previously described . In brief, the coronary arteries were perfused via an arterio-arterial shunt connected extracorporeally. Blood was withdrawn from a femoral artery, passed through a small 250-ml mixing chamber, and returned by three lowflow Sarns perfusion pumps to the cannulated right, main left, and anterior descending coronary arteries. The right coronary artery was perfused from a site just distal to its origin from the aorta, while the left main coronary artery was perfused from a Gregg cannula inserted retrogradely from the left subclavian artery into the coronary ostium. The latter cannulation was used primarily to perfuse the left circumflex artery. The anterior descending artery was perfused separately from a third cannula placed high in the proximal third of its distribution. Pump flows were initially set to make the coronary perfusion pressures equal to that of the systemic mean arterial pressure. Final adjustments were made based on the coronary venous saturations (average 47.2 ± 2.1% at normal flows). Separate venous cannulas were inserted into the great cardiac vein both anteriorly and laterally to sample for oxygen and other metabolites across the two perfusion systems of the left ventricular myocardium. In all animals, the hemiazygos vein, which in swine drains into the coronary sinus, was ligated.
To measure the specifics of carnitine transport, radioactively tagged carnitine was added to the extracorporeal mixing chamber. A stock solution of 50 ml dextran was prepared containing 50/iCi [ I4 C]-L-carnitine and 100fiCi-D-[1~ H]-sorbitol (to estimate extracellular space). The final solution was mixed, transferred to an infusion syringe connected to the mixing chamber of the extracorporeal circuit, and administered at a rate of 1 ml/min over the course of the study.
A high-fidelity, manometer-tipped pressure device was inserted into the left ventricle to measure pressures. A low mechanical impedance strain gauge was attached to the anterior epicardial surface of the heart near the apex in the perfusion distribution of the anterior descending coronary artery . From these data were derived regional shortening, expressed in terms of natural strain(s), i.e., A lengths (L)/L, and integrated work index loops, defined as / left ventricular pressure X ds/dt X dt, throughout a computer-reconstructed cardiac cycle. Heart rate was monitored by electrocardiogram. All hemodynamic data were displayed on an eight-channel Mark 200 Brush, recorded, and processed using a Digital Equipment Corporation PDP 11/10.
Data Analyses
Mechanical function was estimated both globally and regionally. Specific measurements were obtained of heart rate, left ventricular phasic and developed pressures, max dp/dt, regional work loop indices, and epicardial shortening. Metabolic determinations included coronary perfusate levels of oxygen, free fatty acids (FFA), carnitine (total concentration and cpm of added labeled carnitine), and sorbitol (cpm). From these were calculated regional myocardial oxygen consumptions, sorbitol space, and carnitine transport rates (see below). At the conclusion of the studies, tissue samples of left ventricular myocardium from the two perfusion systems (anterior descending and circumflex circulations) were immediately frozen in liquid nitrogen for later analysis. Determinations included tissue levels of highenergy phosphates, acid soluble and long-chain acyl esters of CoA and carnitine, and cpm of labeled carnitine. Methods of measurement and procedure have been described previously (Liedtke et al., 1975; .
With regard to L-carnitine transport measurements, aliquots of neutralized tissue extracts and serum were placed in aqueous scintillation fluid (Amersham/Searle) and their radioactivity determined in a Beckman LS-230 scintillation counter. The specific activities of carnitine in serum and tissue (both acid-soluble and long-chain acyl fractions) were determined from their respective radioactivities and concentrations (expressed as nmol/g dry). Carnitine transport (expressed as nmol/hr per g dry) was then calculated as the quotient of total labeled carnitine (cpm/g dry) present in myocardial intracellular space divided by the specific activity of carnitine in serum (expressed as cpm/nmol). This quotient was then divided by 0.5 hour, the time course of the study. The amount of radioactivity in the intracellular space was estimated by subtracting the tissue radioactivity present in the extracellular space from the total tissue radioactivity. The extracellular space was determined as the distribution space for [ 3 H]-sorbitol (Morgan et al., 1961) . This space averaged 0.30 ± 0.01 ml/g wet in the circumflex bed and 0.32 ± 0.01 ml/g wet in the anterior descending bed. Tissue water content was determined by the differences in weight of powdered tissue before and after drying at 100°C overnight. The terminal serum [ As an additional study in selected animals, arterial blood was examined to test whether the infused labeled carnitine was converted from free to acylated derivatives by passage throughout the body over the course of the perfusion trials. Serum samples were deproteinized with perchloric acid (6% wt/vol). The distribution of radioactivity between free and acetyl carnitine was determined after separation by thin layer chromatography. The neutralized serum extracts were chromatographed on this layer silica plates with a solvent system containing chloroform, methanol, concentrated NH 4 OH, and water (50:40:4:4 vol/vol/vol/vol) (Seim and Strack, 1977) . Known standard solutions of carnitine and acerylcarnitine (Sigma Tau) were chromatographed and visualized by exposure to vaporized iodine. Lanes on the thin layer plates (Whatman LK5D) containing the chromatographed serum extracts were cut in 5-cm sections, scraped into scintillation vials, eluted with 1.0 ml water, and counted. Greater than 95% of the [ 14 C]-L-carnitine in serum was present as the free carnitine moiety.
Experimental Protocol
The purpose of the present studies was to further characterize carnitine transport in the in vivo, blood-perfused, working swine hearts. Permutations of altered coronary flow (high, normal, and ischemic) and perfusate fatty acids (low and high FFA) were provided in part to alter plasma membrane function in the regionally perfused preparation. Animals were divided into three groups, two of which received a constant infusion of an emulsion of triacylglycerols (10% Intralipid) with heparin beginning 20 minutes before the hearts were rendered fully ischemic. This was done to ensure sufficient incorporation of fatty acids into the cell before beginning the major part of the study (final 30 minutes). Ischemia was produced by gradually reducing flow by 59% in the anterior descending circulation over 6 minutes (to avoid serious dysrhythmias) and was maintained at these levels over the final 30 minutes. Flow to the right and left circumflex arteries was held at normal levels throughout the studies. In one of the two fatty acid-augmented groups, coronary flow to the anterior descending and circumflex circulations was maintained at higher flow rates so as to vary oxygen delivery (flow X perfusate hemoglobin content X arterial oxygen saturation in mmol/ hr per g). Thus, three groups of hearts were compared: group 1 (n =8) low FFA with normal and low regional oxygen delivery; group 2 (n = 8) high FFA with normal and low regional oxygen delivery; group 3 (n = 10) high FFA with high and marginally reduced regional oxygen delivery. To measure carnitine transport, [ 14 C]-L-carnitine was administered as an initial bolus followed by a constant infusion into the coronary perfusate, beginning when regional coronary flow was reduced.
Metabolic and mechanical data were obtained at 10-minute intervals and the studies terminated at 30 minutes with the collection of myocardial tissue. All metabolic data were normalized by dry weight of myocardium which was determined by postmortem distributions of green-and black-colored dyes injected separately into the circumflex and anterior descending cannulae. Paired Student's f-tests were used to test for statistical significance of intragroup comparisons. A two-component, aposteriori, statistical analysis was used for intergroup comparisons and included an F test analysis of variance followed by a Studentized Newman-Keuls test (Snedecor and Cockran, 1972) . Significance was defined for probability values of less than 5%. Distribution of the data, where listed, always appears as the standard error of the mean.
Results
Oxygen delivery and serum FFA for the three groups are shown in Figure 1 . Oxygen delivery to the circumflex and anterior descending circulations in groups 1 and 2 (normal oxygen delivery) were nearly identical and statistically different (P < 0.01) at all times from values for group 3 (high oxygen delivery). At -6 minute perfusion time, flow to the anterior descending circulation was reduced from 6.3 ± 0.4 to 2.3 ± 0.3 ml/min per g dry in group 1; from 5.4 ± 0.4 to 2.5 ± 0.2 ml/min per g dry in group 2; and in the hyperperfused group 3 from 8.9 ± 1.0 to 3.8 ± 0.6 ml/min per g dry. The average change in flow was 59%. In animal groups 2 and 3, fatty acid levels were augmented to above 1 /imol/ml in the coronary per- fusate (average values: 1.15 ± 0.03 jumol/ml). These supplements were comparable between groups 2 and 3, and both were statistically different from FFA values in group 1 (mean 0.24 fimol/ml, P < 0.01). As a result of the absolute levels of coronary flow and the vasodilating properties of excess fatty acids as previously shown , perfusion pressures in the anterior descending circulation at control flows were 121, 97, and 143 mm Hg for groups 1, 2, and 3, respectively. These changed to 58, 30, and 53 mm Hg in the three groups at ischemic flows. Changes in global and regional mechanical function are shown in Figure 2 . The effects of ischemia in untreated (group 1) hearts were confined to changes observed in regional contractility. By paired Student's r-test analysis before and after reductions in coronary flow, significant differences (P < 0.005) were observed for systolic shortening (-68 A%) and regional work index (-53 A%) but not for heart rate, left ventricular pressures, or max dp/dt. The inclusion of high fatty acids at similar conditions of oxygen delivery (group 2 hearts) modified these trends. Left ventricular pressures [systolic (-12 A%), diastolic (+108 A%) and developed (-16 A%)] and max dp/dt (-39 A%), as well as systolic shortening (-91 A%) and regional work index (-74 A%) at 30 minutes of perfusion, were reduced significantly from preischemic values (P at least <0.005 by paired Student's t-tests).
Regional work index was decreased significantly at 10 and 20 minutes of perfusion from the levels in untreated hearts. These effects of high FFA were obviated at higher flow rates. At similar levels of serum fatty acids but at significantly higher rates of oxygen delivery than in group 2 hearts (+56 A% for the circumflex bed and + 64 A% for the anterior descending bed), group 3 hearts showed essentially no decline in mechanical function from that at -6 to +30 minutes of perfusion. Rates of oxygen consumption are shown in Figure  3 . Changes in oxygen consumption approximated the patterns of oxygen delivery to the two perfusion beds. Oxygen consumption between -20 and -6 minutes of perfusion increased by 17.4% in the anterior descending bed and by 22.8% in the circumflex bed in hearts receiving high fatty acids. Oxygen consumption in the anterior descending bed declined some 49% (range 45-55% for all three groups, P at least <0.005 by paired Student's r-tests). The differences in consumptions between untreated hearts (group 1) and high FFA-treated hearts (group 2) before and after ischemia were significant (P < 0.01). Absolute levels of oxygen consumption were highest in the marginally reduced LAD bed of group 3 hearts (P at least <0.05 by Studentized Newman-Keuls tests). There were no statistical differences in oxygen consumption among groups for the circumflex bed. Tissue stores of high-energy phosphates followed similar trends. Absolute declines in these stores were greater in the two low flow groups ( -45 A% in sum of creatine phosphate and ATP in the LAD bed for groups 1 and 2 vs. -16 A% in group 3, P < 0.01). Nonischemic values in all groups were comparable.
Long-chain fatty acyl and acid-soluble derivatives of CoA and carnitine are shown in Figure 4 . As expected, reduced coronary flow in untreated hearts increased both long-chain acyl-CoA and carnitine esters (+56 A% and +637 A%, respectively, P at least <0.025). Reciprocal declines in acid-soluble fractions were noted. Inclusion of fatty acids in groups 2 and 3 further increased long chain derivatives of both CoA and carnitine at normal (+64 and +307 A%, respectively) and ischemic (+26 and +57 A%, respectively) flows. These increases were most obvious in the circumflex bed (P at least <0.05 between untreated and group 2 hearts and between untreated and group 3 hearts). There were no essential differences between groups 2 and 3. Elevations of long-chain esters in 
FIGURE 4. Tissue levels of long-chain fatty acyl and acid-soluble derivatives (upper and lower panels) of CoA and camitine (left and right panels) in the three heart groups. In each panel data are displayed by perfusion bed, i.e., circumflex and anterior descending circulations. Symbols and abbreviations as before.
nonischemic tissue of high FFA-treated groups tended to attenuate somewhat the changes noted with ischemia in untreated hearts. Concentrations of total CoA and carnitine were either unchanged or slightly reduced (P < 0.05) in all groups. Incorporation of labeled carnitine into tissue carnitine pools is shown in Table 1. [ 14 C]-L-carnitine in untreated hearts (normal oxygen delivery in the circumflex bed) distributed with the available carnitine pools by the relationship: 95% of cpm/g dry in the acid-soluble fraction vs. 5% of cpm/g dry in the longchain acyl fraction. Treatment with high FFA in groups 2 and 3 increased the percentage of counts in the long-chain ester which was significant (P < 0.05) for group 2 hearts (high FFA-normal oxygen delivery). Specific activity for long-chain acyl carnitine in untreated hearts was somewhat higher than in high FFA-treated hearts due to the lower tissue concentration of the carnitine esters. Specific activities of total carnitine for nonischemic beds in all heart groups were comparable and averaged 3.9 cpm/nmol.
Ischemia caused a further redistribution of counts. In untreated hearts this relationship became: 81% of cpm/g dry in the acid-soluble fraction vs. 19% of cpm/g dry in the long-chain acyl fraction. These shifts were both statistically significant from nonischemic values (P < 0.01 by paired Student's r-tests). Reducing oxygen delivery in high FFA-treated hearts caused similar shifts in counts (average for groups 2 and 3: 79% of cpm/g dry in acid-soluble fraction, 21% of cpm/g dry in long-chain acyl carnitine). Specific activities for acid-soluble carnitine and long-chain acyl carnitine in the anterior descending tissue were comparable for all groups, and the specific activity for the total tissue carnitine averaged 3.0 ± 0.6 cpm/nmol in the three groups (no significant difference among groups).
L-Carnitine transport rates are shown in Figure 5 . Serum carnitine values in the three groups was 7.4 ± 0.6 nmol/ml, while the specific activity averaged 1433 cpm/nmol (range 700-3297 cpm/nmol). Transport rate in untreated nonischemic heart muscle was 18.0 ± 2.0 nmol/hr per g dry. Ischemia significantly but modestly reduced this value (-18 A%, F < 0.01). Excess fatty acids in group 2 nonischemic tissue decreased transport a comparable amount (-24 A%) and in combination with ischemia even further suppressed transport rates below control values (-41 A%, F < 0.005). Interestingly, transport rates in hyperperfused tissue (group 3 hearts) were appreciably increased over values in groups 1 and 2 for both the circumflex (+70 A%) and anterior descending (+104 A%) perfusion beds (P at least < 0.05 by Studentized NewmanKeuls tests). Flow restriction in these hearts produced only a modest 14% fall in transport, which was statistically insignificant from aerobic levels. To ensure that transport rates in ischemic hearts were not dependent upon the delivery rate of labeled carnitine in the perfusate, venous counts were compared with arterial counts at several perfusion times in the anterior descending bed. Results are given in Table 2 . By 30 minutes of perfusion, arterial counts of labeled carnitine had plateaued in each group, and venous counts were not statistically different. Extraction fractions were essentially zero. These data argued that the above reported transport rates of carnitine across sarcolemma was not delivery dependent.
Discussion
The present study was designed to estimate the rates of L-carnitine entry into intact, working swine hearts. Normal transport rates were comparatively slow and only modestly effected by ischemia. This suggests that either the energy demands of the specific L-carnitine carrier sites were small or that some other incorporation mechanism was operative. Fat-loading per se in aerobic tissue had little influence on transport, but the lowest rates occurred in fatty acid-treated ischemic myocardium. Conversely, the highest rates of transport occurred in hyperperfused fatty acidtreated hearts. Rates of transport in this group were higher in both the circumflex and anterior descending perfusion beds.
Specifics of the experimental preparation and methods as well as their critiques have been published previously Liedtke and Nellis, 1979; Liedtke et al., 1981) . Previous studies have established that crosscontamination between perfusion beds is low (<10%) due to either the particular venous drainage patterns in swine heart or the deficit in preformed collateral channels well-known for the species. The rationale of the study was to evaluate the rates of carnitine transport under a variety of conditions postulated to alter sarcolemmal properties or carrier sites. Fatty acids were chosen because of their known inhibitory effects on plasma membranes and enzyme activities (Liedtke, 1981) . Oxygen delivery was varied to alter tissue energy stores, since previous data from cardiac myocyte studies have indicated that the carnitine transport system was carrier-mediated and energy-dependent Bahl et al., 1981) . Results of the present study agreed in general with previous observations, i.e., in the perfused swine heart preparation inclusion of excess fatty acids in the perfusate increased oxygen consumption, promoted further accumulation of fatty acid intermediates in ischemic tissue, and depressed mechanical function . These nonspecific effects may relate to either the actions of fatty acid excess on aerobic or ischemic myocardium or both. Previous data in a globally perfused heart model (ibid) indicated that both actions were operative.
The present data are a measure of the net uptake of [ 14 C]L-carnitine into heart muscle. The distribution of radioactivity into the synthesis of long-chain acyl carnitine supports the conclusion of intracellular incorporation of labeled carnitine. The data also suggest this entry was predominantly unidirectional. At the end of 30 minutes of perfusion, there was still a 367-fold difference in mean specific activities for carnitine between serum and tissue (1453 and 3.5 cpm/nmol, respectively). Such a large disparity indicates that steady state conditions for the distribution of label between pools had not yet occurred and that the movement of radioactivity was predominantly from out-to-within myocytes. Conversely, if the data are viewed by total radioactivity expressed in terms of volume (for serum 7.4 nmol/ml X 1453 cpm/nmol or 10752 cpm/ml vs. 697 nmol/ml X 3.5 cpm/nmol or 2440 cpm/ml for tissue), a ratio of counts of 4.4:1 from serum to tissue is derived. This yields a maximum possible error in the transport calculations of 23% by back diffusion. However, such a figure is a "worst case possible" estimate, is not representative of the entire perfusion period, and assumes that the incorporation process is at all times by diffusion only and that none of the label enters poorly diffusable or bound intracellular pools. The latter two assumptions are highly unlikely, particularly in light of the physiological levels of camitine studied in these experiments. Thus, under the time constraints of the present protocol, the weight of the evidence indicates a unidirectional flux of labeled camitine. This does not imply that net uptake of radioactivity will proceed indefinitely but only until steady state distributions of label are established. Camitine (4-N-trimethylammonium-3-hydroxybutyric acid) is an essential cofactor for long-chain fatty acid oxidation in excitable tissues and has several additional actions in cardiac muscle. In normal myocardium, camitine directly dilates coronary vessels, increases inotropy, slows heart rate, and-like quinidine-is effective against induced supraventricular dysrhythmias ( DiPalma et al., 1975; Brooks et al., 1977; . In ischemic hearts, camitine improves hemodynamics (Vicks et al., 1976) , lessens the ischemic changes by electrocardiogram, reduces levels of ectopic ventricular dysrhythmias (Folts et al., 1978) , and restores levels of high-energy phosphates . We have shown also that camitine in pharmacological doses improves mechanical function in fatty acid-treated ischemic swine hearts, lessens fatty acid incorporation and oxidation, and attenuates the build up of long-chain acyl-CoA. The L-isomer appeared to be the more biologically active Liedtke et al., 1981) .
Such observations have spurred interest in the regulation of camitine metabolism. If the therapeutic effects of camitine administration during ischemia are due to alterations in myocardial fatty acid metabolism, then camitine must be demonstrated to be taken up by the heart. However, little information is available concerning camitine uptake. Injection of [ 3 H]carnitine into rats in vivo resulted in an accumulation of radioactive camitine in heart muscle suggesting that carnitine uptake did occur. The specifics of this uptake were not characterized. Other studies reported for cardiac tissue using either cardiac fetal cells in culture (B0hmer et al., 1977; M0lstad et al., 1977; M0lstad et al., 1978) , isolated adult myocytes (Bahl et al., 1981) , or isolated perfused rat hearts (Vary and Neely, 1981) have confirmed this finding. The latter group demonstrated that about 80% of camitine uptake at physiological concentrations of extracellular camitine occurred by the carrier-mediated system. The present study characterized L-carnitine transport in vivo. The rate of uptake at physiological serum camitine levels was 18 nmol/hr per g dry. The addition of fatty acid slightly decreased camitine uptake. Of interest were the unexpectly high rates of camitine transport in the hyperperfused myocardium. The mechanism of this stimulation is at present unknown. However, the influence of flow upon transport rates does not appear to be dependent upon delivery of camitine as evinced by the absence of appreciable differences between arterial and venous counts of [ 14 C]-L-carnitine at 30 minutes of perfusion in any of the three heart groups ( Table 2 ).
Plasma camitine in these studies averaged 7.4 nmol/ml, while the intracellular camitine concentration for aerobic tissue was 697 nmol/ml (calculated from total tissue carnitine/intracellular water), suggesting that the L-carnitine uptake occurred against a concentration gradient. The transport of camitine against such a gradient indicates an energy-requiring system, which agrees with previous findings. Based on the use of metabolic inhibitors, M0lstad et al. (1977,1978) demonstrated that both 2,4-dinitrophenol and arsenoxide inhibited camitine transport in Girardi heart cells but that potassium cyanide did not. Bahl et al. (1981) also noted an inhibitory effect with 2,4-dinitrophenol. Such data support the notion of an energy-dependent process, but, in both instances, the inhibitory effects with blockers were small. Vary and Neely (1981) did not observe an energy dependence for camitine transport in the perfused rat heart.
The present study suggests that in non-fat-treated hearts, camitine transport was only slightly inhibited during low-flow ischemia (ATP levels decreased by 26%, creatine phosphate by 36%). The lack of a greater inhibitory effect with ischemia suggests that, in intact hearts, the energy source for camitine transport may not be ATP directly. However, the rate of transport observed in vivo was slow (18 nmol/hr per g dry) so that the expected energy requirement would be minimal. Under the present low flow conditions as employed in these studies, the level of ATP in the ischemic myocardium may not have been depleted enough to make it rate-limiting for camitine transport. This finding is of interest with regard to future plans for therapy with camitine. In clinical settings of ischemia in which high-energy phosphate depletions are less than profound, camitine transport into ischemic tissue may be expected to continue. In heart muscle with reduced camitine stores, this replacement may effect benefits in fatty acid metabolism Liedtke, et al., 1981) .
